Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells
试验速览
- 阶段
- 1 期
- 入组人数
- 5
- 试验地点
- 2
- 主要终点
- CT Scan
研究概览
简要总结
The purpose of this study is to investigate the potential use of Wharton's Jelly Mesenchymal stem cells (WJ-MSCs) for treatment of patient diagnosed with Corona Virus SARS-CoV-2 infection, and showing symptoms of COVID-19.
详细描述
COVID-19 is a condition caused by infection with Coronoa Virus (SARS-CoV-2). This virus has a high transmission rate and is spreading at very high rates. causing a worldwide pandemic. Patients diagnosed with COVID-19 and confirmed positive with the virus, will be given three IV doses of WJ-MSCs consisting of 1X10e6/kg. The three doses will be 3 days apart form each other.
Patients will be followed up for a period of three weeks to assess the severity of the condition and measure the viral titers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
盲法说明
None. This is a direct study for the potential effects of WJ-MSCs on COVID-19 outcome.
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •COVID-19 positive according to diagnosis and clinical management of COVID-19 criteria.
排除标准
- •Participants in other clinical trials
- •patients with malignant tumors
- •pregnant and lactating women
- •co-infection with other infectious viruses or bacteria
- •History of several allergies
- •Patients with history of pulmonary embolism
- •any liver or kidney diseases
- •HIV positive patients
- •Considered by researchers to be not suitable to participate in this clinical trial
- •Chronic heart failure with ejection fraction less than 30%.
结局指标
主要结局
CT Scan
时间窗: 3 weeks
Side effects measured by Chest Readiograph
Clinical outcome
时间窗: 3 weeks
Improvement of clinical symptoms including duration of fever, respiratory destress, pneumonia, cough, sneezing, diarrhea.
RT-PCR results
时间窗: 3 weeks
Results of Real-Time Polymerase Chain Reaction of Viral RNA, Turing negative
次要结局
- RT-PCR results(8 weeks)
研究者
Adeeb Al Zoubi
President, Chief Scientific Officer
Stem Cells Arabia